Drugs / KB408
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06049082 | Feb 2024 → Dec 2025 overdue | alpha 1-antitrypsin deficiency | Krystal Biotech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KB408 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06049082 ↗ |
| Route | Inhaled | “via nebulization” NCT06049082 ↗ |
| Target | SERPINA1 | “functional full-length human SERPINA1” NCT06049082 ↗ |